**Core tip:** It is important to investigate factors influencing the healing speed of endoscopic submucosal dissection (ESD)-induced ulcers to prevent gastrointestinal bleeding. Although previous studies have looked at many factors related to ESD-induced ulcer healing, such as location of the tumor, submucosal fibrosis, initial ulcer size, diabetes, and method of gastric acid suppression, this report showed that the severity of gastric atrophy is possible factor to affect speed of ESD-induced ulcer healing. Therefore, *Helicobacter pylori* (*H. pylori*) eradication therapy is required to perform at younger age before progression of gastric mucosal atrophy to prevent development of *H. pylori-*related diseases and bleeding from ESD-induced ulcer.

INTRODUCTION
============

The efficacies of endoscopic submucosal dissection (ESD) and surgical gastrectomy for early-stage gastric cancer are generally similar\[[@B1]\]. ESD, being less invasive, is the first-line treatment for early-stage gastric cancer. ESD allows en bloc resection and is associated with a lower recurrence rate than endoscopic mucosal resection (EMR)\[[@B2],[@B3]\].

Gastrointestinal bleeding from ESD-induced ulceration is a common complication\[[@B4]-[@B7]\]. Factors associated with an increased risk of post-ESD gastrointestinal bleeding include the size, location, and histology of the gastric cancer; kinds of gastric acid suppressant; patient use of dialysis; and long procedure time\[[@B4]-[@B7]\]. The risk of bleeding is reduced by endoscopic coagulation of exposed vessels at the base of ESD-induced ulcers and potent acid inhibition over the first 24 h post-treatment\[[@B4]-[@B7]\]. When ESD is performed for gastric cancer, proton pump inhibitors (PPIs) are used to treat ESD-induced ulcers\[[@B7]\]. However, PPIs may not suppress gastric acid secretion over 24 h, especially at night. Administration is required over several days to maximize gastric acid inhibition. More recently, interindividual genetic variations (*e.g*., CYP2C19 genotype)\[[@B8],[@B9]\] have been linked to different metabolism rates of PPIs. Vonoprazan, a potassium-competitive acid blocker (P-CAB) with more potent and sustained acid inhibition than PPIs, has been approved in Japan\[[@B10]-[@B12]\]. Although vonoprazan inhibits gastric H^+^/K^+^-ATPase similarly to PPIs, its mechanism of acid inhibition involves inhibition of H^+^, K^+^-ATPase by binding reversibly and competitively with K^+^\[[@B13]\]. It remains unclear whether vonoprazan is associated with improved ulcer healing speed and prevention of post-ESD bleeding, due to the low statistical power of the most recent studies\[[@B5],[@B14]\].

Previous studies have looked at many factors related to ESD-induced ulcer healing, such as location of the tumor\[[@B15]\], submucosal fibrosis\[[@B16]\], initial ulcer size\[[@B17],[@B18]\], diabetes\[[@B18]\], coagulation abnormality\[[@B18]\], electrocoagulation during ESD\[[@B18]\], and method of gastric acid suppression\[[@B19]\].

Concurrent *Helicobacter pylori* (*H. pylori*) infection has been found to influence the speed of peptic ulcer healing\[[@B20],[@B21]\]. However, it is unclear whether current *H. pylori* infection and eradication therapy affect the healing of ESD-induced ulcers\[[@B22],[@B23]\]. In addition, there may be an association with the severity of gastritis/gastric atrophy and post-ESD ulcer healing\[[@B23],[@B24]\].

Rapid healing of ESD-induced ulcers is key to the prevention of delayed bleeding. We investigated factors that might be associated with healing of post-ESD ulcers, including *H. pylori* status, profile of the gastric tumor, kinds of acid inhibitory drugs, and severity of gastritis (*e.g*., gastric atrophy and intestinal metaplasia).

MATERIALS AND METHODS
=====================

Patients
--------

We enrolled 132 Japanese patients who underwent ESD for clinical early-stage gastric cancer and adenoma between March 2013 and October 2016 at our institution. Approval for the study protocol was given in advance by the Institutional Review Board of the Shiga University of Medicine Science (Number 27-36). This trial was registered in the University Hospital Medical Information Network, UMIN000018188.

ESD was performed if cases met the following criteria of early-stage gastric cancer and gastric adenoma according to the Union for International Cancer Control/American Joint Committee on Cancer stages: (1) Intramucosal intestinal-type neoplasm without ulceration, regardless of tumor size; (2) intramucosal intestinal-type cancer with ulceration, ≤ 3 cm; (3) intestinal-type cancer invading the submucosa \< 500 μm from the muscularis mucosa, ≤ 3 cm in size; and (4) intramucosal diffuse-type cancer without ulceration, ≤ 2 cm. Exclusion criteria were patients with advanced-stage gastric cancer, patients who refuse follow-up endoscopy at both 4 and 8 wk after ESD treatment and patients with lack of informed consent.

Although severity of anemia and oxygenation were expected to affect the healing speed of ESD-induced ulcer, there were no patients with severe anemia of less than 10 g/mL or hypoxemia.

Study protocol
--------------

For this study, we enrolled patients who had undergone ESD for resection of gastric tumor and provided blood samples for an anti-*H. pylori* IgG serological testing and *CYP2C19* genotyping. The endoscopic severity of gastritis was characterized by the Kyoto classification\[[@B25]\]. According to the Kyoto classification of gastritis, patients are scored according to atrophy (None: A0, atrophic patterns with a margin between the non-atrophic fundic mucosa and atrophic mucosa located in the lesser curvature of the stomach: A1, and atrophic patterns, whose margin does not cross the lesser curvature: A2), intestinal metaplasia (none: IM0, within antrum: IM1, and up to corpus: IM2), hypertrophy of gastric folds (negative: H0, positive: H1), and diffuse redness (negative: DR0, mild: DR1, severe: DR2)\[[@B25]\].

ESD was performed with a single-channel magnifying endoscope (GIF-H290Z or GIF-H260Z; Olympus, Tokyo, Japan). We used a fixed-length disc-tipped knife (Dual knife^®^, KD-650L/Q; Olympus, Tokyo, Japan) or an insulated-tip diathermic knife (IT knife 2^®^, KD-611L, Olympus, Tokyo, Japan) and applied electric current using an electrosurgical generator (VIO300D^®^; ERBE Elektromedizin GmbH, Tubingen, Germany). Visible vessels were heat-coagulated using hemostatic forceps (FD-412LR^®^; Olympus, Tokyo, Japan). After ESD, 73.5% of patients were dosed with lansoprazole 30 mg and 26.5% were dosed with vonoprazan 20 mg (Table [1](#T1){ref-type="table"}) for 8 wk.

###### 

Characteristics of enrolled patients with gastric tumor

  **Parameter**                                         
  ----------------------------------------------------- ------------------------------
  Number                                                132
  Age (yr)                                              71.0 ± 8.6
  Gender (male/female)                                  100/32 (75.8%/34.2%)
  *H. pylori* status (positive/negative)                68/64 (51.5%/48.5%)
  Anti-coagulant administration (+/-)                   22/110 (16.7%/83.3%)
  Acid suppressant post-ESD (lansoprazole/vonoprazan)   97/35 (73.5%/26.5%)
  CYP2C19 genotype (EM/IM/PM)                           40/51/22 (35.4%/45.1%/19.5%)
  Endoscopic background of gastric mucosa               
  Atrophy (Kyoto A0+A1/Kyoto A2)                        20/112 (15.2%/84.8%)
  Intestinal metaplasia (none + mild/severe)            72/55 (56.7%/43.3%)
  Diffuse redness (none/mild/severe)                    65/62 (51.2%/48.8%)
  Tumor                                                 
  Types (adenoma/cancer)                                16/116 (12.1%/87.9%)
  Depth (mucosa/submucosa)                              118/14 (89.4%/10.6%)
  Location of tumors (upper/middle/lower third)         15/67/50 (11.4%/50.8%/37.8%)
  ESD                                                   
  Mean procedure time (min)                             76.4 ± 56.7
  Mean resected ulcer area (mm^2^)                      671.9 ± 720.9
  ESD-induced ulcer area                                
  Reduction at 4 wk                                     90.4% ± 10.7%
  Mean ulcer area at 4 wk (mm^2^)                       71.3 ± 135.6
  Reduction at 8 wk                                     99.8% ± 0.6%
  Mean ulcer area at 8 wk (mm^2^)                       2.8 ± 15.6

EM: Extensive metabolizer of *CYP2C19*; ESD: Endoscopic submucosal dissection; IM: Intermediate metabolizer of *CYP2C19*; PM: Poor metabolizer of *CYP2C19*.

The major and minor axes of ESD-induced ulcers were endoscopically measured the day after ESD by measurement forceps (M2-4K^®^; Olympus Corporation, Tokyo, Japan), and at 4 and 8 wk post-ESD.

H. pylori infection
-------------------

Infection status of *H. pylori* was evaluated based on findings from two tests: an anti-*H. pylori* IgG serological test (E plate Eiken *H. pylori* antibody^®^; Eiken Chemical Co. Ltd., Tochigi, Japan) and a rapid urease test (Helicocheck^®^; Otsuka Co., Tokyo, Japan). When either test was positive, the patient was diagnosed as positive for *H. pylori* infection.

CYP2C19 genotyping
------------------

Genomic DNA was extracted from the blood (DNA Extract All Reagents^®^, Applied Biosystems, Foster City CA, United States). Subsequently, genotyping was performed using a single-nucleotide polymorphism (SNP) genotyping assay (TaqMan^®^, Applied Biosystems) in a real-time polymerase chain reaction (PCR) system (Step One Plus^®^, Applied Biosystems). Genotyping for identifying the *CYP2C19* wild-type gene and two mutated alleles, *CYP2C19 \*2* (rs4244285, A/G) and *\*3* (rs-4986893, G/A) were performed to classify each subject as belonging to one of the following four genotype groups: extensive metabolizers (EMs, \* 1/ \* 1), intermediate metabolizers (IMs; \* 1/ \* 2 or \* 1/ \* 3), or poor metabolizers (PMs; \* 2/ \* 2, \* 2/ \* 3 or \* 3/ \* 3).

Statistical analysis
--------------------

Age, ESD procedure time and ESD-induced ulcer area are expressed as mean ± SD. The healing rates of ulcers were calculated as (1-ulcer area/ulcer area just after ESD) × 100 (%) and are expressed as mean ± SD. Statistical differences in these parameters among CYP2C19 genotypes; between *H. pylori* infection statuses; among degrees of atrophy, intestinal metaplasia, and diffuse redness according to the Kyoto classification; and among tumor locations were determined using one-way ANOVA with Scheffé multiple comparison and Fisher's exact tests. All *P* values are two-sided, and *P* \< 0.05 was considered statistically significant. Calculations were performed using commercial software (SPSS version 20, IBM Inc; Armonk NY, United States).

RESULTS
=======

ESD and ESD-induced ulcers
--------------------------

The mean procedure time was 76.4 ± 56.7 min and the mean resected ESD-induced ulcer area was 671.9 ± 720.9 mm^2^ at Day 1. Procedure time for lesions in the lower third of the stomach (47.5 ± 3.2 min) was significantly shorter than those for the middle and upper thirds \[*vs* middle (85.7 ± 6.6 min), *P* = 0.001, *vs* upper (131.3 ± 17.9 min), *P* \< 0.001, respectively\]. The initial ulcer area in the lower third (456.4 ± 265.2 mm^2^) was significantly smaller than that of the middle third (822.0 ± 922.2 mm^2^, *P* = 0.008).

After ESD, mean ESD-induced ulcer areas at 4 and 8 wk were 71.3 ± 135.6 mm^2^ and 2.8 ± 15.6 mm^2^, respectively, and mean healing rates were 90.4% ± 0.8% at 4 wk and 99.8% ± 0.1% at 8 wk (Figures [1A](#F1){ref-type="fig"} and [2A](#F2){ref-type="fig"}). At 8 wk, mean healing rate in the *H. pylori*-positive group (99.7% ± 0.1%) was significantly lower than that in the negative group (99.9% ± 0.0%, *P* = 0.035). There were no significant differences between mean healing rates for lansoprazole and vonoprazan treatment at 4 and 8 wk (Figures [1B](#F1){ref-type="fig"} and C, 2B and C).

![After endoscopic submucosal dissection endoscopic submucosal dissection, mean endoscopic submucosal dissection-induced ulcer areas at 4 and 8 wk in all patients (A), between *Helicobacter pylori*-positive patients and *Helicobacter pylori*-negative patients (B), between lansoprazole and vonoprazan (C), among patients with no atrophy, mild atrophy and severe atrophy (D), and among different locations of tumor (E). ESD: endoscopic submucosal dissection; *H. pylori*: *Helicobacter pylori*.](WJGE-10-83-g001){#F1}

![After endoscopic submucosal dissection, mean reduction rate of endoscopic submucosal dissection-induced ulcer area at 4 wk in all patients (A), between *Helicobacter pylori*-positive and *Helicobacter pylori*-negative patients (B), between lansoprazole and vonoprazan (C), among CYP2C19 genotypes (EM, IM and PM) (D), among non-atrophy, mild atrophy and severe atrophy (E), and among different locations of tumor (lower third, middle third and upper third) (F). *H. pylori*: *Helicobacter pylori*.](WJGE-10-83-g002){#F2}

Healing rate was associated with the severity of gastric atrophy at 4 wk (A0: 97.9% ± 0.6%, A1: 93.4% ± 4.1%, and A2: 89.7% ± 1.0%, respectively).

In patients with severe gastric atrophy, the healing rate was significantly lower than that in patients with mild or no atrophy (A0 + A1) (*P* \< 0.001 and *P* = 0.010) (Figures [1D](#F1){ref-type="fig"} and [2E](#F2){ref-type="fig"}). In addition, at 4 wk, the mean healing rate in the lower third (92.8% ± 1.2%) was significantly delayed compared to the upper two-thirds (83.7% ± 5.3%, *P* = 0.013) (Figure [1E](#F1){ref-type="fig"} and 2F). After 8 wk, ESD-induced ulcers were scarred in 85.7% (12/14) in the upper third, 89.2% (58/65) of the middle third, and 83.3% (40/48) of the lower third (*P* = 0.657) of the stomach. There was no significant association of healing rates at 4 wk with CYP2C19 genotypes (Figure [2D](#F2){ref-type="fig"}).

Factors affecting ESD-induced ulcer healing
-------------------------------------------

We investigated the healing rate of ESD-induced ulcers by setting up over 90% of ESD-induced ulcer area at 4 wk and 100% at 8 wk. ESD-induced ulcers with ≥ 90% healing at 4 wk were associated with absence of atrophy (*P* = 0.010), depth of gastric tumor (*P* = 0.004), and procedure time *P* = 0.026) (Table [2](#T2){ref-type="table"}). The mean procedure time in the ≥ 90% healing group was significantly shorter than that in the \< 90% healing group (65.6 ± 41.1 min *vs* 89.7 ± 64.0 min, *P* = 0.026). The prevalence of patients with open-type atrophic gastritis in the ≥ 90% healing group was 78.0% (64/82), which was significantly lower than that in the \< 90% healing group (96.0%, 43/45, *P* = 0.01).

###### 

Characteristics of patients who achieved early healing of artificial ulcer area after endoscopic submucosal dissection

                                        **Reduction rate over 90% at 4 wk**   **Reduction rate 100% at 8 wk**                                                                  
  ------------------------------------- ------------------------------------- --------------------------------- ------- --------------------------- -------------------------- -------
  Age (yr)                              70.9 ± 9.3                            71.2 ± 7.3                        0.831   70.4 ± 8.9                  74.1 ± 6.2                 0.047
  Gender (male/female)                  62/20 (75.6%/24.4%)                   33/12 (73.3%/26.7%)               0.777   86/24 (78.2%/21.8%)         8/8 (50.0%/50.0%)          0.021
  *H. pylori* (positive/negative)       42/40 (51.2%/48.8%)                   24/21 (53.3%/46.7%)               0.82    54/56 (49.1%/50.9%)         12/4 (75.0%/25.0%)         0.053
  Anti-coagulants                       13 (15.9%)                            8 (17.8%)                         0.78    16 (14.5%)                  4 (25.0%)                  0.231
  PPI or PCAB (post-ESD)                60/22 (73.2%/26.8%)                   32/13 (71.1%/28.9%)               0.804   82/28 (74.5%/25.5%)         14/2 (87.5%/12.5%)         0.210
  CYP2C19 type (EM/IM/PM)               27/28/15 (38.6/40/21.4)               12/20/7 (30.8/51.3/17.9)          0.522   35/39/19 (37.6/41.9/20.5)   4/9/1 (28.6%/64.3%/7.1%)   0.249
  Gastric mucosa                                                                                                                                                               
  Trophy (Kyoto A0+A1/Kyoto A2)         18/64 (22.0%/78.0%)                   2/43 (4.0%/96.0%)                 0.01    19/91 (17.3%/82.7%)         1/15 (6.3%/93.7%)          0.233
  Metaplasia (none-mild/severe)         51/31 (62.2/37.8)                     21/24 (46.7/53.3)                 0.091   64/46 (58.2/41.8)           8/8 (50.0/50.0)            0.537
  Diffuse redness (none-mild/severe)    44/38 (53.7/46.3)                     21/24 (46.7/53.3)                 0.451   60/50 (54.5/45.5)           7/9 (43.8/56.2)            0.419
  Tumor                                                                                                                                                                        
  Depth (mucosa/submucosa)              78/4 (95.1/4.9)                       35/10 (77.8/22.2)                 0.004   101/9 (91.8 /8.2)           15/1 (93.8/6.2)            0.629
  Location (upper/middle/lower third)   7/39/36/ (8.5/47.6/43.9)              7/26/12 (15.6/57.8/26.6)          0.124   12/58/40 (10.9/52.7/36.4)   2/7/7 (12.4/43.8/43.8)     0.797
  ESD                                                                                                                                                                          
  Mean procedure time (min)             65.6 ± 41.1                           89.7 ± 64.0                       0.026   73.9 ± 52.3                 76.1 ± 41.4                0.872
  Mean resected ulcer area (mm^2^)      544.7 ± 387.1                         809.8 ± 849.8                     0.053   567.3 ± 435.2               1178.5 ± 1520.1            0.130

EM: Extensive metabolizer; ESD: Endoscopic submucosal dissection; IM: Intermediate metabolizer; PCAB: Potassium competitive acid blocker; PM: Poor metabolizer; PPI: Proton pump inhibitor; *H. pylori*: *Helicobacter pylori*.

In achievement of scar formation at 8 wk, the rates were associated with gender (*P* = 0.021) and age (*P* = 0.047), but not gastritis or tumor-related factors (Table [2](#T2){ref-type="table"}).

In the univariate analysis to identify possible factors related to achievement of 90% healing at 4 wk, healing was associated with gastric atrophy (OR = 6.047, 95%CI: 1.334-27.403, *P* = 0.019), procedure time (OR = 1.009, 95%CI: 1.002-1.017, *P* = 0.018) and initial ESD-induced ulcer size (OR = 0.001, 95%CI: 1.000-1.001, *P* = 0.032) (Table [3](#T3){ref-type="table"}). At 8 wk, gender and initial ESD-induced ulcer size significantly correlated with the achievement of scarring at 8 wk (*P* = 0.021 and *P* = 0.013, respectively) (Table [3](#T3){ref-type="table"}).

###### 

Univariate analysis of factors preventing healing of ulcers after endoscopic submucosal dissection

                                                               **Reduction rate over 90% at 4 wk**   **Reduction rate 100% at 8 wk**                          
  ------------------------------------------------------------ ------------------------------------- --------------------------------- ---------------------- -------
  Age (yr)                                                     1.004 (0.963-1.048)                   0.841                             1.058 (0.987-1.135)    0.113
  Gender (female *vs* male)                                    1.127 (0.491-2.588)                   0.777                             3.583 (1.218-10.545)   0.021
  *Helicobacter pylori*                                        1.088 (0.525-2.255)                   0.820                             3.111 (0.945-10.244)   0.053
  Lansoprazole *vs* vonoprazan                                 1.108 (0.493-2.488)                   0.804                             0.418 (0.089-1.956)    0.210
  Anti-coagulants                                              1.148 (0.436-3.018)                   0.780                             1.958 (0.561-6.832)    0.231
  CYP2C19 type (EM *vs* IM/PM)                                 1.084 (0.635-1.850)                   0.768                             0.921 (0.420-2.020)    0.838
  Atrophy (Kyoto A0+A1 *vs* Kyoto A2)                          6.047 (1.334-27.403)                  0.010                             3.132 (0.390-25.163)   0.233
  Tumor located in upper and middle third (*vs* lower third)   0.465 (0.211-1.026)                   0.055                             1.361 (0.471-3.934)    0.568
  Mean procedure time (min)                                    1.009 (1.002-1.017)                   0.018                             1.001 (0.991-1.011)    0.871
  Mean resected ulcer area (mm^2^)                             1.001 (1.000-1.001)                   0.032                             1.001 (1.000-1.001)    0.013

EM: Extensive metabolizer; IM: Intermediate metabolizer; PM: Poor metabolizer.

In the multivariate analysis including gender, *H. pylori* infection, endoscopic severity of atrophy, tumor location, mean procedure time, and mean initial ESD-induced ulcer size, the factor associated with 90% healing at 4 wk was gastric atrophy (OR = 5.678, 95%CI: 1.190-27.085, *P* = 0.029) (Table [4](#T4){ref-type="table"}). The factors associated with scarring at 8 wk were gender (female, OR = 4.438, 95%CI: 1.253-15.724, *P* = 0.021) and initial ESD-induced ulcer size (1.001, 1.000-1.002, *P* = 0.023) (Table [4](#T4){ref-type="table"}).

###### 

Multivariate analysis of factors preventing healing of ulcers after endoscopic submucosal dissection

                                                               **Reduction rate over 90% at 4 wk**   **Reduction rate 100% at 8 wk**                          
  ------------------------------------------------------------ ------------------------------------- --------------------------------- ---------------------- -------
  Gender (male *vs* female)                                    1.833 (0.715-4.698)                   0.207                             4.438 (1.253-15.724)   0.021
  Helicobacter pylori                                          1.012 (0.463-2.213)                   0.976                             3.340 (0.866-12.885)   0.080
  Atrophy (Kyoto A0+A1 *vs* Kyoto A2)                          5.678 (1.190-27.085)                  0.029                             2.764 (0.309-24.711)   0.363
  Tumor located in upper and middle third (*v*s lower third)   0.698 (0.283-1.724)                   0.436                             1.848 (0.493-6.933)    0.362
  Mean procedure time (min)                                    1.007 (0.997-1.017)                   0.194                             0.998 (0.982-1.015)    0.850
  Mean resected ulcer area (mm^2^)                             1.000 (1.000-1.001)                   0.443                             1.001 (1.000-1.002)    0.023

ESD-related adverse events
--------------------------

Two patients (1.5%) experienced delayed bleeding with tarry stool and only one patient received transfusion treatment after ESD treatment. Although the prevalence of patients received anti-coagulants was 16.7% and no cases with hematologically abnormal coagulation ability were observed (Table [1](#T1){ref-type="table"}), intake of aspirin of non-steroidal anti-inflammatory drug did not increase incidence of gastric bleeding after ESD. There were no other major ESD-related adverse events.

DISCUSSION
==========

The healing speed of ESD-induced ulcers may be a key factor in preventing ESD-related bleeding. In this study, we investigated possible risk factors associated with healing of ESD-induced ulcers and found that of all possible factors, severe gastric atrophy at 4 wk post-ESD and initial ulcer size at 8 wk were independent risk factors in multivariate analysis. However, we found no significant association of healing of ESD-induced ulcers and tumor location\[[@B15]\], initial ulcer size\[[@B17],[@B18]\], coagulation abnormality\[[@B18]\], electrocoagulation during ESD\[[@B18]\], or kind of gastric acid suppressant\[[@B19]\]. Because the healing rate of ESD-induced ulcers was affected by tumor size, post-ESD ulcer size and severity of gastritis (*e.g*., gastric atrophy), attention should be paid to the incidence of complications (*i.e*., bleeding and perforation) in patients with severe gastric atrophy and a large size of gastric tumor.

In this study, we focused on the influence of the severity of gastric atrophy on the healing rate of ESD-induced ulcers. Previously, Fujiwara et al\[[@B24]\] reported improved healing at 8 wk post-ESD for patients with severe atrophic gastritis when treated concomitantly with a PPI and rebamipide. In this study, at 4 wk after ESD, we revealed that severe gastric atrophy, especially of the A2 type according to the Kyoto classification, slowed healing speed. Kakushima et al\[[@B23]\] failed to show a significant association between the severity of gastric atrophy and ESD-induced ulcer healing with administration with omeprazole and sucralfate for 8 wk post-ESD; our study also did not demonstrate significant differences at 8 wk post-ESD. At 8 wk, mean reduction rates were 99.8% ± 0.1% and ESD-induced ulcers were scarred in 83.3% (110/132). We therefore hypothesize that the severity of gastric atrophy may influence healing of ESD-induced ulcers at 4 wk, but not at 8 wk.

Intestinal metaplasia is often observed in patients with severe gastric atrophy and is a well-known risk factor for gastric cancer, similar to severe gastric atrophy alone. The prevalence of intestinal metaplasia in *H. pylori*-positive patients is 57% in Japanese aged approximately 70 years\[[@B26]\]. Although we saw no significant association between the severity of intestinal metaplasia and ulcer healing speed in this study, Chen et al\[[@B27]\] reported that patients with intestinal metaplasia had a higher healing rate of gastric ulcers than those without intestinal metaplasia, suggesting that patients with severe gastric atrophy accompanied by intestinal metaplasia should be considered as likely candidates for ESD-related complication, due to delayed ulcer healing.

In general, peptic ulcer healing has been correlated with intragastric pH\[[@B28]\], *H. pylori* infection\[[@B20]\], gastric motility\[[@B29]\], microcirculation in gastric mucosa\[[@B30]-[@B32]\], gastric mucosal levels of growth factors\[[@B33],[@B34]\] and prostaglandins (PGs)\[[@B35]\]. The aggressive factors induced gastric mucosal injury resulting in loss of mucosal barrier can be quickly healed if adequate supply of PGE~2~, epidermal growth factor and tumor growth factor (TGF) α takes place. Although it is unclear whether peptic ulcers and ESD-induced ulcers share a similar healing mechanism, because severity of gastric mucosal atrophy reduced microcirculation in gastric mucosa and gastric mucosal levels of prostaglandin and growth factors, resulted that advanced gastric atrophy perturbs the process of ulcer healing in the presence of these above factors.

Association with intragastric pH and speed of post-ESD ulcer healing
--------------------------------------------------------------------

Vonoprazan has a longer half-life (7.7 h) than PPIs, due to its slow dissociation from H^+^/K^+^-ATPase\[[@B36]\]. In addition, vonoprazan inhibits H^+^/K^+^-ATPase activity with 400-fold greater potency than lansoprazole at pH 6.6\[[@B37]\]. Therefore, use of vonoprazan for treatment of ESD-induced ulcers is expected to confer an advantage over the conventional regimen with a PPI. This is despite the finding of Kagawa et al\[[@B5]\], who reported that the rates of ESD-related ulcer healing were 96.0% ± 6.7% at 6 wk with vonoprazan and 94.7% ± 11.6% at 8 wk with PPI, despite the fact the post-ESD bleeding incidence in the vonoprazan group (1.3%) was less than that in the PPI group (10.0%, *P* = 0.01). In a prospective randomized controlled trial, the rate of scar formation attained with vonoprazan at 8 wk was significantly higher than that for esomeprazole (94.9% *vs* 78.0%, *P* = 0.049), and in a multivariate analysis, only vonoprazan was correlated with scar formation (OR = 6.33; 95%CI: 1.21-33.20)\[[@B14]\]. However, although we have two kinds of clinical pathways scheduled to use lansoprazole or vonoprazan after ESD treatment for gastric tumors and investigated to analyze the healing speed of ulcer after ESD by use of only the two kinds of acid inhibitory drugs, lansoprazole and vonoprazan, there was no significant difference between vonoprazan and lansoprazole at 4 wk and 8 wk after ESD in this study. Given that one factor associated with healing of ESD-induced ulcers at 8 wk in multivariate analysis was initial ulcer size, this discrepancy may be due to differences in the size of lesions. Although potent acid inhibition is required to heal ESD-induced ulcers, a 90% reduction in ESD-induced ulcers was achieved at 28 d, irrespective of acid inhibitors. It is important to investigate whether the kind of acid inhibitor influences the speed of artificial ulcer reduction in an earlier phase (*i.e*., within 2 wk).

Limitations
-----------

Several limitations of this study warrant mention. First, the sample size is not large. Second, we did not gather data regarding the reduction rate at 2 wk post-ESD. In this study, most ESD-induced ulcers had already healed by 4 wk post-ESD, which means evaluation at an earlier phase is required. Third, although we investigated the influence of CYP2C19 genotype, which impacts the pharmacodynamics of PPI, on the healing of ulcers, we did not clarify whether the CYP3A4/5 genotype, which is related to vonoprazan-dependent pharmacodynamics, influenced healing\[[@B38]\]. Forth, although minerals (*e.g*., Zn) and vitamins (*e.g*., Vitamin C) may affect the healing speed of ulcer after ESD, unfortunately, we have no data of minerals and vitamins in all patients\[[@B39],[@B40]\].

In conclusions, we conducted a study to investigate factors influencing the healing speed of ESD-induced ulcers. Healing speed was affected by the severity of gastric atrophy, but not by *H. pylori* status, kinds of acid inhibitory drugs, or CYP2C19 genotype. These results suggest that eradication of *H. pylori* can be carried out at any time in terms of ulcer healing and that PPI or vonoprazan treatment for ESD-induced ulcers can be administrated at the standard dose irrespective of CYP2C19 genotype.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The endoscopic submucosal dissection (ESD) for early-stage gastric cancer is first-line therapy in Japan, because of en bloc resection and a lower local recurrence rate of gastric cancer. However, bleeding from ESD-induced ulcer is a major complication of ESD treatment. When ESD is performed for gastric cancer, PPIs or vonoprazan are used to treat ESD-induced ulcers in Japan. It remains unclear whether vonoprazan with more potent and sustained acid inhibition than PPIs, *H. pylori* infection and characteristics of gastric mucosa (*e.g*., inflammation and atrophy) are associated with improved ulcer healing speed and prevention of post-ESD bleeding. Rapid healing of ESD-induced ulcers is key to the prevention of delayed bleeding.

Research motivation
-------------------

Of many possible factors related to ESD-induced ulcer healing, such as location of the tumor, submucosal fibrosis, initial ulcer size, diabetes, coagulation abnormality, electrocoagulation during ESD, and method of gastric acid suppression, it is unclear whether above parameters actually affect the healing of ESD-induced ulcers and the incidence of gastrointestinal bleeding after ESD treatment. Especially, there was no report investigated with the healing speed of ulcer after ESD and characteristics of gastric mucosa (*e.g*., inflammation and atrophy).

Research objectives
-------------------

The main objective was to clarify factors that might be associated with healing of post-ESD ulcers and bleeding, including *H. pylori* status, profile of the gastric tumor, kinds of acid inhibitory drugs, and severity of gastritis including of gastric atrophy and intestinal metaplasia.

Research methods
----------------

We retrospectively enrolled 132 patients with gastric tumors scheduled for ESD, irrespective to *H. pylori* infection. Following ESD, patients were treated with daily lansoprazole 30 mg or vonoprazan 20 mg for 8 wk. Ulcer size was endoscopically measured on the day after ESD and at 4 and 8 wk. The gastric mucosa was endoscopically graded according to the Kyoto gastritis scoring system. We assessed the number of patients with and without a 90% reduction in ulcer area at 4 wk post-ESD and scar formation at 8 wk, and looked for risk factors for slower healing.

Research results
----------------

After ESD, mean healing rates of ESD-related ulcer were 90.4% ± 0.8% at 4 wk and 99.8% ± 0.1% at 8 wk. The reduction rate was associated with the Kyoto grade of gastric mucosal atrophy at 4 wk and ESD-induced ulcers with ≥ 90% healing at 4 wk were associated with absence of atrophy, depth of gastric tumor, and procedure time. In the univariate analysis to identify possible factors related to achievement of 90% healing at 4 wk, healing was associated with gastric atrophy, procedure time and initial ESD-induced ulcer size. In the multivariate analysis, the factor associated with 90% healing at 4 wk was gastric mucosal atrophy (OR = 5.678, 95%CI: 1.190-27.085, *P* = 0.029).

Research conclusions
--------------------

The healing speed of ESD-induced ulcers was affected by the severity of gastric atrophy, but not by *H. pylori* status, kinds of acid inhibitory drugs, or CYP2C19 genotype. Patients with severe gastric atrophy accompanied by intestinal metaplasia should be considered as likely candidates for ESD-related complication, due to delayed ulcer healing. Therefore, *H. pylori* eradication therapy is required to perform at younger age before progression of gastric mucosal atrophy to prevent development of *H. pylori-*related diseases and bleeding from ESD-induced ulcer.

Research perspectives
---------------------

Eradication of *H. pylori* can be carried out at any time in terms of ulcer healing and that PPI or vonoprazan treatment for ESD-induced ulcers can be administrated at the standard dose irrespective of CYP2C19 genotype. However, because this is a preliminary small study, further study is required to plan whether the healing speed of ESD-induced ulcers was affected by the severity of gastric atrophy in prospective multicenter study. In addition, we will clarify the potential mechanism about association with the healing of ESD-induced ulcer and severity of gastric atrophy as further study.
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